BC Week In Review | Nov 18, 2013
Clinical News

E6201: Development discontinued

Eisai disclosed in its 2Q13 earnings for the period ending Sept. 30 that it discontinued development of E6201. The product was in Phase II testing in the U.S. and EU to treat psoriasis. Eisai Co....
BC Innovations | Dec 9, 2010
Cover Story

Melanoma: three ways around BRAF inhibition

Independent research teams have identified three mechanisms by which melanoma can develop resistance to BRAF inhibitors, 1,2 a promising class of therapeutics that include late-stage clinical compounds from Plexxikon Inc. and GlaxoSmithKline plc . The findings...
BC Innovations | Jun 10, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer; gastric cancer; melanoma BRAF; CRAF (RAF1); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2) Genomic and in vitro studies suggest that RAF1 and...
BC Week In Review | May 31, 2010
Clinical News

E6201: Phase I data

In an open-label, dose-escalating Phase I trial in 25 patients with advanced solid tumors, E6201 led to 1 case of stable disease for >10 months in a patient with metastatic ocular melanoma and 1 partial...
BC Innovations | May 13, 2010
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Gastrointestinal disease Adenomatous polyps MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); myeloid differentiation primary response gene 88 (MYD88) Mouse studies suggest that blocking the...
BC Week In Review | Nov 9, 2009
Company News

Quintiles Transnational Corp., Eisai deal

CRO Quintiles will conduct Phase II proof-of-concept trials for 11 solid tumor indications for six of Eisai's cancer programs. Quintiles will fund the trials and is eligible for milestones. The deal includes Ontak denileukin diftitox,...
Items per page:
1 - 6 of 6